These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36090728)

  • 41. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
    Augustin M; Reich K; Yamauchi P; Pinter A; Bagel J; Dahale S; You R; Bruin G; Djimopoulos J; Paguet B; Charef P; Patekar M; Keefe D
    Br J Dermatol; 2022 Jun; 186(6):942-954. PubMed ID: 34981829
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Definition of treatment goals for moderate to severe psoriasis: a European consensus.
    Mrowietz U; Kragballe K; Reich K; Spuls P; Griffiths CE; Nast A; Franke J; Antoniou C; Arenberger P; Balieva F; Bylaite M; Correia O; Daudén E; Gisondi P; Iversen L; Kemény L; Lahfa M; Nijsten T; Rantanen T; Reich A; Rosenbach T; Segaert S; Smith C; Talme T; Volc-Platzer B; Yawalkar N
    Arch Dermatol Res; 2011 Jan; 303(1):1-10. PubMed ID: 20857129
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study.
    Gargiulo L; Ibba L; Pavia G; Vignoli CA; Piscazzi F; Valenti M; Sanna F; Perugini C; Avagliano J; Costanzo A; Narcisi A
    Dermatol Ther (Heidelb); 2022 Oct; 12(10):2309-2324. PubMed ID: 36063283
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
    Menter A; Feldman SR; Weinstein GD; Papp K; Evans R; Guzzo C; Li S; Dooley LT; Arnold C; Gottlieb AB
    J Am Acad Dermatol; 2007 Jan; 56(1):31.e1-15. PubMed ID: 17097378
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
    Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars.
    Ruiz-Argüello MB; Maguregui A; Ruiz Del Agua A; Pascual-Salcedo D; Martínez-Feito A; Jurado T; Plasencia C; Balsa A; Llinares-Tello F; Rosas J; Torres N; Martínez A; Nagore D
    Ann Rheum Dis; 2016 Sep; 75(9):1693-6. PubMed ID: 26965981
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study.
    Megna M; Fornaro L; Potestio L; Luciano MA; Nocerino M; Delfino M; Guarino M; Fabbrocini G; Camela E
    Psoriasis (Auckl); 2022; 12():199-204. PubMed ID: 35844291
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ixekizumab for treatment of moderate to severe plaque psoriasis: real world clinical experience.
    Diotallevi F; Campanati A; Radi G; Molinelli E; Offidani A
    G Ital Dermatol Venereol; 2020 Dec; 155(6):739-743. PubMed ID: 30428651
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial.
    Cohen SB; Radominski SC; Kameda H; Kivitz AJ; Tee M; Cronenberger C; Zhang M; Hackley S; Rehman MI; von Richter O; Alten R
    BioDrugs; 2020 Apr; 34(2):197-207. PubMed ID: 31939063
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
    Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
    J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Efficacy of infliximab in patients with moderate and severe psoriasis treated with infliximab (Remicade)].
    Valdés A Mdel P; Schroeder H F; Roizen G V; Honeyman M J; Sánchez M L
    Rev Med Chil; 2006 Mar; 134(3):326-31. PubMed ID: 16676105
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Secukinumab Demonstrated High Effectiveness in Vietnamese Patients with Moderate-To-Severe Plaque Psoriasis in a Real-World Clinical Setting: 16 Week Results from an Observational Study.
    Nguyen HT; Pham NTU; Tran TNA; Nguyen NTT; Vu TTP
    Dermatol Ther (Heidelb); 2021 Oct; 11(5):1613-1621. PubMed ID: 34275123
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study.
    de Vries AC; Thio HB; de Kort WJ; Opmeer BC; van der Stok HM; de Jong EM; Horvath B; Busschbach JJ; Nijsten TE; Spuls PI
    Br J Dermatol; 2017 Mar; 176(3):624-633. PubMed ID: 27416891
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
    Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients].
    Puig L
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():30-5. PubMed ID: 19080989
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study.
    Megna M; Potestio L; Fabbrocini G; Ruggiero A
    Psoriasis (Auckl); 2022; 12():205-212. PubMed ID: 35859710
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Five-year experience with infliximab: Follow up of the product familiarisation program.
    Nguyen R; Braue A; Baker C; Foley P
    Australas J Dermatol; 2016 Nov; 57(4):300-306. PubMed ID: 26374405
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2).
    Reich K; Wozel G; Zheng H; van Hoogstraten HJ; Flint L; Barker J
    Br J Dermatol; 2013 Jun; 168(6):1325-34. PubMed ID: 23621698
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Treatment of severe refractory psoriasis with infliximab].
    Mahiques Santos L; Martínez-Menchón T; Sánchez Carazo JL; Oliver Martínez V; Soriano Navarro CJ; Fortea Baixauli JM
    Med Clin (Barc); 2004 Nov; 123(17):657-8. PubMed ID: 15563800
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Cost-per-Number Needed to Treat Analysis Assessing the Efficiency of Biologic Drugs in Moderate to Severe Plaque Psoriasis.
    Núñez M; Huete T; de la Cueva P; Sacristán JA; Hartz S; Dilla T
    Actas Dermosifiliogr (Engl Ed); 2019 Sep; 110(7):546-553. PubMed ID: 30851873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.